Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of New RPH-104 Formulation in Healthy Volunteers
NCT07206043Phase 1Completed
- Sponsor
- R-Pharm
- Start
- Dec 2024
- Primary completion
- Feb 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of goflikicept in recurrent pericarditis (7 cohorts), sponsored by R-Pharm. Primary endpoints: Area Under the Plasma Concentration-Time Curve at Day 61, Maximum Plasma Concentration at Day 61 and 2 more. Started Dec 2024; status: completed.
02
Drugs
goflikicept
03
Conditions
recurrent pericarditis
Beyond the preview
Go deeper on NCT07206043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07206043.